UNSPSC 51391745: Isoetharine mesylate

This classification denotes a bronchodilator and beta-adrenergic agonist with the molecular formula C13H21NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DV74WJ5PJB, chemically known as 3,4-dihydroxy-alpha-(1-(isopropylamino)propyl)benzyl alcohol methanesulfonate (salt) but more generally known as isoetarine mesilate, which bears U.S. National Institutes of Health Compound Identifier 23702.

UNSPSC 51391745 Isoetharine mesylate, a Commodity code, shows minimal alignment with the recent state and local solicitation activity tagged under it. Isoetharine mesylate is a bronchodilator medication used in respiratory treatment, but the single recent opportunity under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems, products unrelated to the code's nominal pharmaceutical scope. The mismatch suggests either a data-entry error in the county's tagging or a misalignment between the code's definition and how it is applied in practice at the issuing level.

Seminole County posted the naloxone and deactivation-systems IFB on June 30, 2026, with a response deadline of July 26, 2023 (an apparent date inconsistency in the source), seeking 1,900 units of naloxone and 800 deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county requires electronic bid submission, fixed-fee pricing with unit costs per line item, E-Verify compliance, drug-free workplace certification, and standard commercial liability and workers' compensation insurance. The contract carries a two-year initial term with one optional one-year renewal and includes a three-month probationary termination clause. No explicit set-aside designations are noted, though the procurement may be FEMA-funded, which would impose Clean Air Act and Federal Water Pollution Control Act compliance requirements. Given the narrow recent activity and the scope mismatch, the code does not present a reliable signal for business development in pharmaceutical procurement at the state and local level.